Industry analyzers IMS Health and BCC Research estimate that the global pharmaceutical market will grow at about a 5% rate in 2009 to over $820 billion and be worth over $1 trillion by 2013. Pharmaceutical and biotechnology companies in the US spent approximately $59 billion on R&D in 2007, which equates to roughly 18% of their sales and is a 5% increase from the previous year. A significant portion of R&D budgets are used for the outsourcing services offered by the CRO industry, approximately $15 billion in 2007. This figure is expected to grow at 15% over the next seven years and should increase further with the broadening of the spectrum of services outsourced to cover the entire value chain. As outsourced services in developing countries such as China and India move up the value chain to cover various phases of trials, the total contracts value may go up to $20 billion by 2010. Further, certain therapeutic areas within pharmaceutical development are slated for an even greater growth curve, namely the oncology class, expected to see continued growth of upwards of 21% over the next few years due to the large target market, strong unmet medical need, and overwhelming number of drugs currently in development (667 for cancer vs. 252 for CNS disorders, 206 for cardiovascular disorders, and 186 for infections). There are over 1,100 companies in the world. It is a very fragmented industry with the top 10 controlling 56.1% of the market in 2008.